Moreover, the combination of the FABP5‐targeting nanocarrier co‐delivery system with RFA and anti‐PD‐L1 monoclonal antibodies constitutes a promising and effective therapeutic strategy for HCC. The gene discussed is FABP5; the disease is hepatocellular carcinoma.